Market Overview

PARP Inhibitors in Oncology | A Drug Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest pipeline analysis report on the PARP
inhibitors in oncology
. The report includes a detailed analysis
of the pipeline molecules under investigation within the defined data
collection period for PARP inhibitors in oncology.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180731005988/en/

Technavio has published a new report on the drug development pipeline for PARP inhibitors in oncolog ...

Technavio has published a new report on the drug development pipeline for PARP inhibitors in oncology, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

PARP inhibitors: Market overview

Poly-ADP ribose polymerase (PARP) inhibitor is a targeted class of
cancer drugs. PARP is a protein present in cells of the human body,
which helps the damaged cells to repair themselves by playing a role in
various DNA repair pathways. PARP inhibitors inhibit the repair of DNA
damage in the cell and thus result in the accumulation of deleterious
mutations leading to genetic instability.

According to a senior market research analyst at Technavio, "The PARP
inhibitors are undergoing development for the treatment of various
cancer types such as breast cancer, ovarian cancer, prostate cancer,
pancreatic cancer, lung cancer, and gastric cancer. According to the
Center for Disease Control and Prevention report, the national
expenditure for the care of cancer in the US, in 2017, was USD 147
billion, which is expected to rise further due to the high cost of new
drugs and adoption of advanced treatment options as standards of care."

PARP inhibitors in oncology: Segmentation
analysis

This pipeline analysis report segments the PARP inhibitors in oncology
market based on therapies employed (monotherapy, monotherapy/
combination therapy, and combination therapy), RoA (oral and
inhalational), therapeutic modality (small molecule), geographical
segmentation (Asia, Americas and EMEA) and recruitment status (active,
but not recruiting, completed, not yet recruiting, and recruiting). It
provides an in-depth analysis of the prominent factors influencing the
market, including drivers, opportunities, trends, and industry-specific
challenges.

Based on the route of administration, 85% of the molecules that are
being investigated for PARP inhibitors in oncology are oral drugs.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!